Market Snapshot: Qingdao Baheal Pharmaceutical on the Rise
The latest trading session for Qingdao Baheal Pharmaceutical (301015.SZ) concluded with the share price unchanged, trading flat at 0 % during the 24‑hour period that ended at 04:03 AM Central Europe on Thursday, 22 September 2026. Investors can acquire a share of the company for approximately CNY 22.30 on the major exchanges that list it.
Trading Volume and Capitalisation
In the past 24 hours, the total value of Qingdao Baheal shares exchanged amounted to CNY 186.3 million, against a market‑capitalisation benchmark of CNY 11.7 billion. The current available supply of shares is 525.6 million. The company’s price has slipped 14.6 % since the end of last month, signalling a gradual downward trend amid broader market volatility.
Technical Indicators
The 200‑day simple moving average sits at CNY 23.11, a level above today’s trading price of CNY 22.30. Over the last year, the highest point reached CNY 28.77 on 20 April 2026, while the lowest was CNY 18.40 on 25 June 2026. These figures suggest a relatively tight trading range, with modest volatility compared to the broader market.
Peer Performance
In the same 24‑hour window, several peer companies in the Chinese market exhibited varied movements:
| Company | Symbol | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| Rlx | RLX | –1.75 % | USD 1.68 | USD 2.10 bn | 15.27 |
| Zibo Qixiang Tengda Chemic | 002408.SZ | 0 % | CNY 4.86 | CNY 14 bn | — |
| Ningbo Joyson Electronic | 0699.HK | +1.42 % | HKD 10.71 | HKD 16.4 bn | 21.54 |
| Apichope Pharmaceutical Group | 300723.SZ | 0 % | CNY 30.56 | CNY 14 bn | 63.65 |
| Jinyu Bio‑Lt | 600201.SS | 0 % | CNY 12.91 | CNY 14.1 bn | 98.9 |
While Qingdao Baheal’s share price remained stagnant, peers such as Ningbo Joyson Electronic posted modest gains, and others like Rlx experienced slight declines. The varied performance underscores the sector’s fragmented nature, with companies reacting differently to market sentiment and sector-specific developments.
Company Overview
Qingdao Baheal Pharmaceutical Co., Ltd. is headquartered in Shenzhen, China, and trades on the Shenzhen Stock Exchange. The firm specialises in the development, manufacturing, and distribution of pharmaceutical products, targeting both domestic and international markets. Its portfolio spans a range of therapeutic categories, positioning it as a mid‑cap player within China’s rapidly evolving healthcare sector.
This article provides an objective overview of Qingdao Baheal Pharmaceutical’s recent market activity and situates it within the broader landscape of Chinese pharmaceutical equities.
